Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Neoplasms 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Prostatic Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Head and Neck Neoplasms 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Nephrotic Syndrome 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Bevacizumab 2Temozolomide 1Radiotherapy 1Phlebotomy 1Pharmaceutical Preparations 1Nivolumab 1HMPL-013 1Fluoxetine 1Cisplatin 1Cholecalciferol 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Adenocarcinoma × Pharmaceutical Preparations × Clear all
NCT05635149 2022-12-02

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Unknown
100 enrolled
Gastrointestinal

Colorectal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡